Obesity due to prohormone convertase I (PCSK1) deficiency: A Patient Guide
At a Glance
PCSK1 deficiency is a rare genetic disorder that may cause severe diarrhea and poor weight gain in infancy, followed by biologically driven, intense hunger and obesity. Children need coordinated nutrition, hormone monitoring, emergency planning, and specialist treatment.
Obesity due to prohormone convertase I (PCSK1) deficiency is an exceptionally rare genetic condition that fundamentally changes how a child’s body communicates with itself. At its core, the condition is a disorder of hormone processing: the body lacks a vital biological “cutter” (the PC1/3 enzyme, encoded by the PCSK1 gene) required to activate several essential hormones. Because these hormones control everything from how we digest food to how we perceive hunger and manage stress, their absence creates a complex, changing medical landscape that evolves as a child grows [1].
For many families, the journey begins with a “biphasic” or two-phase clinical course that can be deeply confusing. In infancy, the lack of active hormones can lead to severe, watery diarrhea and difficulty absorbing nutrients, making it a struggle for the child to gain weight. As the child moves into toddlerhood, the digestive issues often stabilize, but they may be replaced by a new challenge: an intense, insatiable hunger known as hyperphagia. This hunger is not a behavioral issue but a direct result of the brain being unable to receive the “fullness” signals it needs to regulate appetite, which can lead to rapid weight gain [2][3].
Living with this condition requires a focus on four key areas of care. First is the early management of nutrition and hydration to support growth during the digestive phase. Second is the vigilant, individualized monitoring of the endocrine system, as the missing enzyme can cause various hormone deficiencies—such as issues with growth, thyroid function, and the body’s stress response—at different stages of life. Third is the recognition that the intense hunger is biological in nature, requiring specialized medical treatments rather than solely traditional lifestyle changes. Finally, because the condition is so rare, success depends on a dedicated, multidisciplinary care team that can coordinate these different needs [4][5].
What You Should Do Next
- Confirm the diagnosis: Work with a clinical geneticist to ensure the genetic interpretation is correct.
- Establish a care team: Identify an expert endocrinology and gastroenterology contact.
- Create an emergency plan: Obtain a written sick-day and adrenal action plan for your child.
- Assess treatment options: Discuss whether targeted medications are appropriate for your child’s specific age and genetic profile.
While a diagnosis of PCSK1 deficiency marks the end of a difficult search for answers, it also marks the beginning of a proactive management plan. By understanding the underlying biology, you can better advocate for your child and work with specialists to provide the hormonal and nutritional support they need. This guide is designed to help you navigate each step of that journey, providing the knowledge to empower your family and your medical team [6].
In this guide
6 chapters
Understanding PCSK1 Deficiency: A Guide for Parents and Caregivers
Learn how PCSK1 deficiency causes infant diarrhea, intense hunger, obesity, hormone problems, and blood sugar changes, plus treatment and monitoring options.
When to Act: Warning Signs and Emergency Care
Learn when prohormone convertase I (PCSK1) deficiency needs emergency care, including dehydration, adrenal crisis, seizures, and low blood sugar in children.
The Biology of Hormone Processing and Diagnosis
Learn how PCSK1 deficiency affects hormone processing, why genetic tests can miss it, and how proinsulin and symptoms support diagnosis and guide next steps.
The Endocrine Journey: Long-Term Monitoring and Care
Learn how PCSK1 deficiency is monitored over time, including growth, thyroid, adrenal, water-balance, blood sugar, and puberty checks for children as they grow.
From Malabsorption to Management: Treatment and Therapy
Learn how PCSK1 deficiency is treated, from parenteral nutrition for infant diarrhea to setmelanotide for hyperphagia, obesity, and side-effect monitoring.
Building Your Care Team and Partnering with Experts
Learn how families can build a PCSK1 deficiency care team, prepare for expert visits, coordinate local doctors, and advocate for children with rare obesity.
Common questions in this guide
What is PCSK1 deficiency, and how can it affect a child?
Why can a child with PCSK1 deficiency develop diarrhea first and intense hunger later?
Which specialists should care for a child with PCSK1 deficiency?
What should families do after a child is diagnosed with PCSK1 deficiency?
Is the intense hunger caused by PCSK1 deficiency a behavior problem?
Get notified when new evidence is published on Obesity due to prohormone convertase I deficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (6)
- 1
PCSK1 Variants and Human Obesity.
Ramos-Molina B, Martin MG, Lindberg I
Progress in molecular biology and translational science 2016; (140()):47-74.
PMID: 27288825 - 2
A novel mutation of PCSK1 responsible for PC1/3 deficiency in two siblings.
Duclaux-Loras R, Bourgeois P, Lavrut PM, et al.
Clinics and research in hepatology and gastroenterology 2021; (45(6)):101640 doi:10.1016/j.clinre.2021.101640.
PMID: 33662777 - 3
Novel Homozygous Inactivating Mutation in the PCSK1 Gene in an Infant with Congenital Malabsorptive Diarrhea.
Aerts L, Terry NA, Sainath NN, et al.
Genes 2021; (12(5)) doi:10.3390/genes12050710.
PMID: 34068683 - 4
A New Case of PCSK1 Pathogenic Variant With Congenital Proprotein Convertase 1/3 Deficiency and Literature Review.
Pépin L, Colin E, Tessarech M, et al.
The Journal of clinical endocrinology and metabolism 2019; (104(4)):985-993 doi:10.1210/jc.2018-01854.
PMID: 30383237 - 5
The melanocortin pathway and energy homeostasis: From discovery to obesity therapy.
Yeo GSH, Chao DHM, Siegert AM, et al.
Molecular metabolism 2021; (48()):101206 doi:10.1016/j.molmet.2021.101206.
PMID: 33684608 - 6
Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial.
Argente J, Verge CF, Okorie U, et al.
The lancet. Diabetes & endocrinology 2025; (13(1)):29-37 doi:10.1016/S2213-8587(24)00273-0.
PMID: 39549719
This page is for informational purposes only and does not constitute medical advice. Your child’s geneticist, endocrinologist, and gastroenterologist should interpret the diagnosis and guide individualized nutrition, hormone, and medication decisions.